Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Inclusion Criteria

• •Patients who are diagnosed with Crohn's disease (according to the Crohn's disease diagnostic criteria developed by the research group on intractable inflammatory bowel disorders \[Shimoyama group, January 25, 2002\]) at least 24 weeks before the starting date of the observation period
• •Patients with Crohn's Disease Activity Index (CDAI) score ranging from 220 to 450 inclusive during the observation period
• •C-reactive protein (CRP) of 1 mg/dL or higher in the laboratory test performed at the start of the observation period